Hidoc Dr | Medical Learning App for Doctors

Today's Updates

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

Published Date: 23 Oct 2026

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

CHEST 2026: Day 3 Recap — 6 Headlines to Know

Published Date: 23 Oct 2026

CHEST 2026: Day 3 Recap — 6 Headlines to Know

What the Next Accelerated TMS Trial Should Test, With Jonathan Downar, MD Jonathan Downar, MD, PhD

Published Date: 23 Oct 2026

Downar outlines the randomized trial needed to confirm optimal TMS dosing and addresses a safety ceiling on total pulses.

NeuroVoices: Bruce Bebo, PhD, on Big Bets for Breakthroughs and the Campaign to End MS Bruce Bebo, PhD, Isabella Ciccone, MPH

Published Date: 23 Oct 2026

The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.

Divozilimab Cuts Relapse Risk at 1 Year in Phase 3 AQUARELLE Trial of NMOSD Marco Meglio

Published Date: 23 Oct 2026

One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.

Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis Marco Meglio

Published Date: 23 Oct 2026

Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.

FDA Grants Fast Track to AV-1959R for Alzheimer Prevention Matt Hoffman

Published Date: 23 Oct 2026

Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.

CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS Isabella Ciccone, MPH

Published Date: 23 Oct 2026

Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.

Inside FIND-CKD: The Data Behind the Trial's 23% Risk Reduction Brendon Neuen, MBBS, PhD, Shikha Wadhwani, MD, MS

Published Date: 23 Oct 2026

Brendan Neuen breaks down the full FIND-CKD primary and secondary endpoint data, subgroup consistency, and safety signals.

Inside FIND-CKD: Can Finerenone Pair With Immunosuppression in GN? Brendon Neuen, MBBS, PhD, Shikha Wadhwani, MD, MS

Published Date: 23 Oct 2026

Brendon Neuen explains why finerenone's mechanism supports combining it with immunosuppressive therapy in glomerulonephritis.

Knowledge Hub

Oncology

Tumor-Associated Fibroblast Metabolites as Biomarkers of Stromal Activity

Evidence-based review on tumor-associated fibroblast metabolites as clinical biomarkers of stromal activity.

Oncology

Exposure-Response in Immuno-Oncology: Mechanisms, Clinical Insights, and Practical Implications

A comprehensive medical review on exposure-response in immuno-oncology, covering mechanisms, clinical insights, and practice implications.

Oncology

Circulating Metabolic Signatures of Tumor Nutrient Competition

Review of circulating metabolic signatures in tumor nutrient competition and their clinical implications for oncology.

Oncology

Therapeutic Advances in Cancer-Associated Fibroblast Reprogramming

A comprehensive review of emerging therapies targeting cancer-associated fibroblast reprogramming for improved cancer care.

Oncology

KOL Videos

Hidoc Dr| Hidoc- US| Hidoc - Doctor Netwoking Platform| Educational resource for HCPs

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Your one-stop Solution for MEDICAL LEARNING & UPDATES

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

CHEST 2026: Day 3 Recap — 6 Headlines to Know

What the Next Accelerated TMS Trial Should Test, With Jonathan Downar, MD Jonathan Downar, MD, PhD

NeuroVoices: Bruce Bebo, PhD, on Big Bets for Breakthroughs and the Campaign to End MS Bruce Bebo, PhD, Isabella Ciccone, MPH

Divozilimab Cuts Relapse Risk at 1 Year in Phase 3 AQUARELLE Trial of NMOSD Marco Meglio

Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis Marco Meglio

FDA Grants Fast Track to AV-1959R for Alzheimer Prevention Matt Hoffman

CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS Isabella Ciccone, MPH

Inside FIND-CKD: The Data Behind the Trial's 23% Risk Reduction Brendon Neuen, MBBS, PhD, Shikha Wadhwani, MD, MS

Inside FIND-CKD: Can Finerenone Pair With Immunosuppression in GN? Brendon Neuen, MBBS, PhD, Shikha Wadhwani, MD, MS

Knowledge Hub

Tumor-Associated Fibroblast Metabolites as Biomarkers of Stromal Activity

Exposure-Response in Immuno-Oncology: Mechanisms, Clinical Insights, and Practical Implications

Circulating Metabolic Signatures of Tumor Nutrient Competition

Therapeutic Advances in Cancer-Associated Fibroblast Reprogramming

Strength Training During Cancer Recovery: Evidence-Based Clinical Insights

Assessing Therapy-Related Myeloid Neoplasm Risk Through Clonal Hematopoiesis and Treatment Exposure Integration

Pediatric Tumor Microenvironment Models for Laboratory Research

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Page Views

Your one-stop Solution for MEDICAL LEARNING & UPDATES

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

CHEST 2026: Day 3 Recap — 6 Headlines to Know

What the Next Accelerated TMS Trial Should Test, With Jonathan Downar, MD Jonathan Downar, MD, PhD

NeuroVoices: Bruce Bebo, PhD, on Big Bets for Breakthroughs and the Campaign to End MS Bruce Bebo, PhD, Isabella Ciccone, MPH

Divozilimab Cuts Relapse Risk at 1 Year in Phase 3 AQUARELLE Trial of NMOSD Marco Meglio

Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis Marco Meglio

FDA Grants Fast Track to AV-1959R for Alzheimer Prevention Matt Hoffman

CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS Isabella Ciccone, MPH

Inside FIND-CKD: The Data Behind the Trial's 23% Risk Reduction Brendon Neuen, MBBS, PhD, Shikha Wadhwani, MD, MS

Inside FIND-CKD: Can Finerenone Pair With Immunosuppression in GN? Brendon Neuen, MBBS, PhD, Shikha Wadhwani, MD, MS

Knowledge Hub

Tumor-Associated Fibroblast Metabolites as Biomarkers of Stromal Activity

Exposure-Response in Immuno-Oncology: Mechanisms, Clinical Insights, and Practical Implications

Circulating Metabolic Signatures of Tumor Nutrient Competition

Therapeutic Advances in Cancer-Associated Fibroblast Reprogramming

Strength Training During Cancer Recovery: Evidence-Based Clinical Insights

Assessing Therapy-Related Myeloid Neoplasm Risk Through Clonal Hematopoiesis and Treatment Exposure Integration

Pediatric Tumor Microenvironment Models for Laboratory Research

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Verification

Welcome to Hidoc Dr.

Page Views